Eloxx Pharmaceuticals, Inc.
ELOX
$0.00
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 52.16% | 59.12% | 46.39% | 47.73% | 24.05% |
| Total Depreciation and Amortization | -0.53% | 42.31% | -6.06% | -11.88% | -32.26% |
| Total Amortization of Deferred Charges | -64.03% | -64.93% | -3.23% | 18.03% | 54.44% |
| Total Other Non-Cash Items | -76.81% | -4.06% | -14.77% | -62.13% | -60.57% |
| Change in Net Operating Assets | 41.86% | 4,430.30% | -409.92% | -214.89% | -276.23% |
| Cash from Operations | 50.33% | 78.80% | 28.21% | 43.00% | 8.46% |
| Capital Expenditure | -- | -- | -- | 100.00% | 30.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 585.42% | 300.00% | 200.00% | 100.00% | 30.43% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -71.27% | -- | -- | -- | 380.77% |
| Cash from Financing | 144.67% | -- | -207.14% | 295.00% | -55.29% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 108.25% | 93.60% | -471.66% | 47.10% | -27.71% |